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Logistic regressionAtypical antipsychotic (AAP) drugs are the preferred choice of treatment for schizophrenia patients. Patients
who do not show favorable response to AAPmonotherapy are subjected to random prolonged therapeutic treat-
ment with AAP multitherapy, typical antipsychotics or a combination of both. Therefore, prior identiﬁcation of
patients' response to drugs can be an important step in providing efﬁcacious and safe therapeutic treatment.
We thus attempted to elucidate a genetic signature which could predict patients' response to AAPmonotherapy.
Our logistic regression analyses indicated the probability that 76% patients carrying combination of four SNPs
will not show favorable response to AAP therapy. The robustness of this prediction model was assessed using
repeated 10-fold cross validation method, and the results across n-fold cross-validations (mean accuracy=
71.91%; 95%CI=71.47–72.35) suggest high accuracy and reliability of the prediction model. Further validations
of these results in large sample sets are likely to establish their clinical applicability.
© 2013 Elsevier Inc. All rights reserved.1. Introduction
Schizophrenia (SZ) is a severe neuropsychiatric disorder with a
wide range of social disabilities, which necessitate life-time treatment
with antipsychotic drugs [1]. Atypical antipsychotic (AAPs) drugs are
the preferred choice of treatment for SZ as they have been shown to
cause less severe adverse reactions as compared to the previously
prescribed typical antipsychotics (TAPs). Nevertheless, the response
to AAPs is highly variable among individuals. The antipsychotic
administration follows a “hit-and-trial”method in absence of a mech-
anism based pre-designed medication regime, till an efﬁcacious drug
for each patient is hit upon. Delay inﬁnding the right drug or treatment
failure often leads to increase in disease severity, side effects, medica-
tion non-compliance or relapse [2,3]. Antipsychotic drug response is a
complex trait, likely to be inﬂuenced by a number of genetic variables
in conjunction with clinical, demographic and environmental factors
which lead to highly heterogeneous response among individuals [4].
Delineating the role of such variables can play an important role, Typical Antipsychotics; SZ,
s; DSM IV, Diagnostic and
n; NIMHANS, National Institute
es for Clinical Assessment in
l Impressions; SPSS, Statistical
alue; NPV, Negative Predictive
Under the Curve.
rights reserved.in predicting appropriate treatment regime for SZ patients. In this
scenario, it is imperative to employ pharmacogenomic approaches to
understand the drug response heterogeneity and devise mechanisms
to predict right choice of treatment regime for SZ patients. The signiﬁ-
cance of such studies for optimizing drug therapies is immense,
especially for long term therapeutics treatments, which are a major
cost-burden on healthcare system.
In the past two decades, numerous efforts have been undertaken
to unveil the key genetic variants related to antipsychotic drug
response variability among SZ patients. A majority of the AAPs are
dopamine–serotonin antagonists, with their primary targets being
dopamine receptor D2 and serotonin receptor 5-HT2A. Studies have
demonstrated that these drugs are effective D2 receptor antagonists,
leading to depolarization blockade of dopamine neurons [5]. Seroto-
nin receptor antagonism facilitates dopamine release and neurotrans-
mission in the prefrontal cortex, thereby accounting for the beneﬁcial
effects of AAPs against the negative symptoms of schizophrenia [5].
On this basis, a number of studies have investigated and reported
the plausible pharmacogenetic role of SNPs from dopamine receptor
genes (DRD1, DRD2, DRD3, DRD4) and serotonin receptor genes
(HTR1A, HTR2A, HTR2C, HTR3A, HTR3B, HTR6 and HTR7) [6–16].
However, these efforts have been thwarted by underpowered study
designs, resulting inmodest predictive power and limited clinical utility
of single pharmacogenetic markers. The importance of elucidating
genetic interactions is gaining wide recognition since concurrent effect
of multiple gene polymorphisms may inﬂuence drug response [17].
Detecting and characterizing interactions between these polymorphisms
can be important in discovering genetic contributors of drug response.
In view of these facts, the present study attempts to elucidate the
Table 1
Demographic and clinical characteristics of schizophrenia patients.
Characteristics Total
(n=371)
Males
(n=224)
Females
(n=147)
p-value⁎
Mean age at assessment
(years; mean±SD)
29.52±7.38 29.26±7.13 30.07±7.94 0.315
Mean age of onset
(years; mean±SD)
25.23±7.07 25.13±6.54 24.40±7.82 0.720
Duration of illness
(years; mean±SD)
4.08±2.68 4.02±3.38 4.41±2.87 0.269
Severity of illness
(CGI-S; mean±SD)
3.43±1.42 3.47±1.41 3.37±1.45 0.506
SD: Standard deviation.
⁎ p-values were calculated using two-tailed Student's t-test.
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response to AAP monotherapeutic treatment. We have previously
evaluated the role of 61 single nucleotide polymorphisms (SNPs)
in response to AAP monotherapy [18]. These SNPs had been selected
from nine genes, which include four dopamine receptor genes (DRD1,
DRD2, DRD3, DRD4) and ﬁve serotonin receptor genes (HTR1A, HTR2A,
HTR2C, HTR3A, HTR3B). Our results indicated initial signiﬁcance of 13
SNPs (p-valueb0.05), among which two serotonin receptor variants
(rs878567/HTR1A and rs1176744/rsHTR3B) were signiﬁcant after ap-
plying tests for multiple comparisons. For performing tests for multiple
comparisons, 10,000 permutationswere carried out for all SNPs in order
to calculate a value that controls for all tested SNPs by comparing each
observed test statistic against the maximum of all permuted statistics
[18]. Nevertheless, it is unlikely that individual SNPs can account for
the variability observed in patients' drug response. Several reports
suggest that multiple SNPs, even of small effect, may interact synergis-
tically to inﬂuence such complex traits [19,20]. Therefore, in the present
study,we have evaluated the interaction of all the SNPswhich showed a
trend towards associationwith AAP response (p-valueb0.1), in order to
establish a genetic analytical model with high accuracy for predicting
drug response to AAP monotherapy.2. Material and methods
2.1. Study design
Three hundred and seventy one schizophrenia patients of south
Indian origin, diagnosed according to Diagnostic and Statistical Man-
ual of Mental Disorders Fourth Revision (DSM IV) criteria and
recruited through the clinical services of the National Institute of
Mental Health and Neurosciences (NIMHANS), India were included
in the present study. Further assessments with structured interviews
were conducted by experienced psychiatrists using Schedules for
Clinical Assessment in Neuropsychiatry (SCAN; WHO) [21]
and OPCRIT 3.1 (MRC, Social, Genetic and Developmental Psychiatry
Centre, Camberwell, South London) [22]. Ethical approval for
this study was obtained from the Institutional Review Board of
NIMHANS.
The study design, patient assessments, genotyping and quality
control (QC) measures have been published previously [18]. Brieﬂy,
371 SZ patients were subjected to evaluation by Clinical Global
Impressions (CGI) scale [23], using the global improvement module,
at the time of enrollment and after three months of mono-
therapeutic treatment with AAPs. The prescribed drugs included
oral doses of risperidone (2–10 mg/day), olanzapine (5–20 mg/day),
clozapine (25–400 mg/day), ziprasidone (40–160 mg/day), quetiapine
(1200 mg/day), aripiprazole (10–45 mg/day) and amisulpride
(100–600 mg/day). The patients were not controlled for their medica-
tions, and the drug prescriptions as well as patient assessments were
carried out by experienced clinicians blind to the patients' genotypes.
A rating of 2 or less on the CGI scale, or a fall in CGI scores by 2
points was classiﬁed as complete response. On the other hand,
CGI score of 3 and above, denoting moderate to poor response
was classiﬁed as incomplete response. Based on these criteria,
192 patients were classiﬁed as complete responders and 179
patients as incomplete responders to AAP treatment. Further on,
complete patient history, their medication, follow-up of all the
patients including patient relapse, non-compliance and change
of treatment were documented. Patient demographic and clinical
factors including age at assessment, age of onset and duration of
illness were also recorded and severity of illness was assessed
at the time of patient enrollment using CGI (Table 1). Blood
samples were obtained from all the subjects after obtaining written
informed consents and genomic DNA was isolated as described else-
where [24,25].2.2. Statistical analyses
In the present study, we investigated the synergistic inﬂuence of
SNPs associated (p-valueb0.05) or showing trend towards association
(p-valueb0.1) with AAP response. These included ﬁfteen SNPs
spanning dopamine and serotonin receptor genes: DRD1 (rs265967),
DRD3 (rs10934254) HTR1A (rs6295, rs878567, rs1423691), HTR2C
(rs3795182, rs3813928, rs2428707, rs1414334, rs1801412) and
HTR3B (rs3758987, rs1176744, rs2307599, rs2276307, rs2276308)
[Supplementary Table S1]. For these genetic variants, we included the
genotype data previously published by Gupta et al. [18]. The overall
genotype call ratewas 97.9%. For the present analysis, themissing geno-
type data (2.1%)was imputed using fastPHASE software [26]. Two SNPs
(rs1423691 and rs2428707) were dropped from the analysis as they
showed complete correlation with rs6295 and rs1414334, respectively
[Supplementary Table S1]. Multivariate logistic regression analysis
was performed for 13 SNPs, using Statistical Package for Social Sciences
(SPSS, version 16.0, SPSS Corporation, Chicago, Illinois, USA) to identify
combinations of multilocus genotypes that are associated with AAP
response. The predictive values of this genetic interaction model were
calculated by using response to antipsychotics as the dependent
variable, and the genetic variants as independent variables. Further,
this genetic model was adjusted for the confounding effects of non-
genetic parameters including age of onset, gender, duration and severity
of illness. Both forward and backward stepwise regression methods
were employed using the block method to identify interaction models
and calculate total accuracy, sensitivity, speciﬁcity, positive and nega-
tive predictive values for all possible models. Sensitivity was deﬁned
as the correct identiﬁcation of patients showing complete response to
antipsychotic treatment, and speciﬁcity as the correct identiﬁcation
of patients showing incomplete response to antipsychotic treatment.
The positive predictive value (PPV) indicated the probability that a
patient with the risk factor (in this case, patient with the predictive
genotype/allele) will show subsequent response to antipsychotic treat-
ment, and the negative predictive value (NPV) reﬂected the probability
that a patient without the risk factor will show incomplete response to
antipsychotic treatment. Receiver operating characteristic (ROC) curve
that displays the trade-off between the sensitivity (true positive rate)
and (1-speciﬁcity) (false positive rate) was generated to further assess
the ability of this genetic interaction model to discriminate between
complete and incomplete responders. Area under the ROC curve (AUC),
considered as an effective measure of inherent validity of a diagnostic
test, was also calculated. The AUC range has been described from 0.5
(non‐informative) to 1 (perfect test discrimination) [27]. The perfor-
mance of the proposed prediction model was assessed using repeated
n-fold cross validation method, where 10 fold cross validations were
repeated 100 times iteratively. Brieﬂy, the datasetwas randomly divided
into 10 parts; 9 parts were used as training set and 1 part as testing
set for ﬁrst fold analysis of 10-fold cross validations. Stepwise logistic
regression function was used to ﬁt the prediction model using the
training dataset, following which this function was used to predict the
Fig. 1. Receiver Operating Characteristic (ROC) curve. The ﬁgure represents the predictive
values (sensitivity and speciﬁcity) and area under the curve (AUC) for the predictive
model.
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such that each of the 10 data-partswas used exactly once as a testing set.
The 10 fold cross validations were repeated 100 times, and the accuracy
of the prediction model (i.e., the probability of correctly classifying
patients' response to AAP monotherapy) for each cross validation was
computed. An in-house script was developed using R software to carry
out the above analysis. The prediction accuracies across fold-validations
have been plotted using a violin plot, which depicts both box plot as
well as probability density of the data. Further, the performance of the
prediction model was assayed by calculating the mean accuracy and
95% conﬁdence intervals (CI) for the predicted accuracies of the model.
3. Results
The 371 SZ patients enrolled for the study comprised of 60% (n=
224) males and 40% (n=147) females. The demographic and clinical
parameters including, age of patients, age at onset, duration and
severity of illness did not vary signiﬁcantly (p-value>0.05) between
the male and female patients (Table 1). Further, the backward step-
wise multivariate logistic regression analysis using the block method
revealed an interaction model with four genetic markers after adjust-
ment with the clinical and demographic variables including gender,
age of onset, duration and severity of illness. These four markers
include rs265967 (DRD1), rs10934254 (DRD3), rs878567 (HTR1A)
and rs1176744 (HTR3B) (Table 2). This interaction model has an
overall accuracy of 73.6% to predict response to AAPs (χ2=117.29,
p-valueb0.0001). The model could account for 38.2% variability in
response to AAPs (Nagelkerke R2=0.382). Further, ROC curve was
generated to assess the ability of this genetic interaction model to dis-
criminate between complete and incomplete responders. The identi-
ﬁed interaction model has sensitivity (ability to predict complete
response to AAPs) of 71.2% and speciﬁcity (ability to predict incom-
plete response to AAPs) of 76% (Fig. 1). The predictive values of this
model are 75.5% (PPV) and 71.8% (NPV). The AUC for this predictive
model was 0.736, indicating a robust power of this model to discrim-
inate between complete and incomplete responders of AAP therapy.
N-fold cross validation analysis was then carried out to check how
well the prediction model generalizes to a new data. The analysis
revealed a normal distribution for prediction accuracies obtained across
10 fold cross validations performed 100 times. This has been depicted
using a violin plot (Fig. 2). The mean accuracy of the proposed model
is 71.91% (95%CI=71.47–72.35).
Further, stepwise multivariate logistic regression analysis was
also carried out for a subgroup comprising of 270 patients treated
with single monotherapy drug group, risperidone. The analysis
revealed a similar prediction model as was observed for 371 multidrug
monotherapy group (Table 3, Supplementary Fig. 1). This model
comprised of three genetic markers [rs10934254 (DRD3), rs878567Table 2
Logistic regression analysis results predicting atypical antipsychotic response.
Variables in the model Multivariate analysisa
β p-Value OR (95% CI)
DRD1/rs265967 −0.40 0.045 0.66 (0.44–0.99)
DRD3/rs10934254 −0.31 0.034 0.72 (0.54–0.97)
HTR1A/rs878567 0.69 0.026 2.00 (1.08–3.69)
HTR3B/rs1176744 0.71 0.009 2.04 (1.19–3.49)
Gender 0.10 0.693 1.11 (0.66–1.86)
Age of onset (AOO)b 0.06 0.819 1.06 (0.63–1.17)
Duration of illnessc −0.38 0.163 0.68 (0.40–1.16)
Severity of illness −0.82 b0.001 0.43 (0.35–0.54)
β: estimated coefﬁcient; p-value: statistical signiﬁcance of each coefﬁcient (β) in the
model tested by Wald test; OR: odds ratio; and CI: conﬁdence interval.
a Stepwise backward multivariate logistic regression analysis.
b Dichotomised usingmean value as early AOO (b25.23 yrs) and late AOO (>25.23 yrs).
c Dichotomised using mean value as short (b4.08 yrs) and long duration of illness
(>4.08 yrs).(HTR1A) and rs1176744 (HTR3B), adjusted with variables including
gender, age of onset, duration and severity of illness] and accounted
for 36.7% variability in response to risperidone (Accuracy=72.3%,
Sensitivity=66.4%, Speciﬁcity=77.6%).
4. Discussion
In the present study, we examined the synergistic inﬂuence of
thirteen dopamine and serotonin receptor polymorphisms on response
to AAP monotherapy using multivariate logistic regression analysis.
These polymorphisms have been previously reported to show aAccuracy
0.55 0.60 0.65 0.70 0.75
 
0.80 0.85
Fig. 2. Violin plot. The violin plot represents combination of the box plot and probability
distribution of prediction accuracies across repeated 10-fold cross validations.
Table 3
Logistic regression analysis results predicting response to risperidone monotherapy.
Variables in the model Multivariate analysisa
β p-Value OR (95% CI)
DRD3/rs10934254 −0.47 0.008 0.62 (0.44–0.88)
HTR1A/rs878567 0.47 0.207 1.61 (0.76–3.40)
HTR3B/rs1176744 0.74 0.020 2.10 (1.12–3.92)
Gender 0.29 0.351 1.33 (0.72–2.45)
Age of onset (AOO)b 0.01 0.961 1.01 (0.55–1.84)
Duration of illnessc −0.26 0.400 0.76 (0.41–1.41)
Severity of illness −0.83 b0.001 0.43 (0.33–0.56)
β: estimated coefﬁcient; p-value: statistical signiﬁcance of each coefﬁcient (β) in the
model tested by Wald test; OR: odds ratio; and CI: conﬁdence interval.
a Stepwise backward multivariate logistic regression analysis.
b Dichotomised using mean value as early AOO (b25.23 yrs) and late AOO (>25.23 yrs).
c Dichotomised using mean value as short (b4.08 yrs) and long duration of illness
(>4.08 yrs).
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devoid of confounding effects owing to population stratiﬁcation [18].
The overall accuracy of these single genetic markers for predicting re-
sponse to AAPs ranged from53.1% to 57.4%, indicatingmoderate predic-
tive abilities, which limits their clinical diagnostic value [Supplementary
Table S1]. These results suggest that predictions using individual SNPs
might account for modest effects on drug response. Therefore, the
synergistic effect of the combination of genetic variableswas elucidated.
The multivariate logistic regression analysis indicated signiﬁcant role of
combination of four genetic variables, rs265967/DRD1, rs10934254/
DRD3, rs878567/HTR1A and rs1176744/HTR3Bwhichhad robust predic-
tive values (overall accuracy=73.6%, PPV=75.4% and NPV=71.8%).
In addition, repeated n-fold cross validations were carried out to
evaluate the performance of the prediction model. The mean accuracy
(71.91%) and 95% CI (71.47–72.35) across n-fold cross validations
suggests that this prediction model can predict patients' response to
AAP monotherapy with high accuracy and reliability in different
conditions.
Further comparison between the single SNP predictive models and
the interaction model in our study revealed the higher odds ratios
(ORs) and predictive ability of the interaction model. The odds of
responding toAAP treatment ranged from1.38 to 2.45 for the individual
SNPs. The OR increased to 7.83 when all markers of the interaction
model were considered. Moreover, the single SNPs could account for
just 0.9–4.2% variability in response to AAPs (Nagelkerke R2=0.009–
0.042). In contrast, R2 value for the predictive model was 0.382, indicat-
ing that this model accounts for 38.2% variability in response to AAPs.
Our results indicate that accounting for marker interactions signiﬁcantly
increased the predictive power for discrimination of complete and
incomplete responders to AAP treatment. The present study thus accen-
tuates the advantage of combined information from response-related
genes which could be used to form the basis of prediction tests.
The signiﬁcance of evaluating the role of synergistic interactions
was ﬁrst demonstrated by Arranz et al. [19] who reported a combina-
tion of six polymorphisms which were able to predict response to
clozapine treatment with an overall accuracy of 67%, and prediction
values 76.8% (PPV) and 80% (NPV). Another study has elucidated
genetic signatures predicting response to iloperidone, wherein a combi-
nation of six genotypes predicted response to iloperidone with an odds
ratio greater than 9.5 [20]. Parallelly, the predictive model revealed
in our study could discriminate among complete or incomplete
responders to AAP monotherapy with a high accuracy of 76.6%.
This model could correctly identify 71.2% patients who were likely to
respond to AAP monotherapy (sensitivity). The predictive model also
enables identiﬁcation of 76% patients unlikely to respond to AAP
monotherapy (speciﬁcity). Prior identiﬁcation of patients with a highprobability of not responding to AAP monotherapy can prevent the
unnecessary delay in ﬁnding the right antipsychotic treatment regime
for the SZ patients. This can also check the increase in disease severity,
side effects or medication non-compliance which may occur due to
prolonged random treatments with different antipsychotics.
Additionally, our subgroup analysis using 270 patients treated with
risperidone monotherapy revealed a similar model as was observed
earlier with 371 AAP monotherapy patient group (Supplementary
Fig. 1). This model was able to correctly identify 77.6% patients unlikely
to respond to risperidone monotherapy (Table 3). Further studies
incorporating evaluation of other genes which might play a direct
or supplementary role in modulating antipsychotic response can
enable establishment of better predictive models for antipsychotic
response and help in unraveling the genetic architecture underlying
drug response. The validation of suchmodels in large cohorts will then
deﬁne the translation of pharmacogenomics into clinical practice for
optimal drug treatment and improved therapeutic outcomes.
5. Conclusion
To the best of our knowledge, this is the largest study with
schizophrenia patients of same ethnicity that examined the combi-
natorial effect of genetic factors likely to inﬂuence the response to
AAP monotherapy. Our results suggest the probability that 76%
patients carrying genotypic combination of four SNPs, rs265967–
rs10934254–rs878567–rs1176744 will not show favorable response
to AAP therapy. Elucidation of such genetic signatures will enable
prior identiﬁcation of patients unlikely to respond to AAP treatment.
Schizophrenia patients likely to show moderate or poor response
to AAP monotherapy can be treated with other alternatives such as
antipsychotic multitherapy. Further studies can establish better predic-
tive models for single antipsychotic monotherapy groups, and their
validations using large sample sets and prospective study design
can determine their clinical applicability for pharmacogenetic tests.
This would reduce cost burden and delay in ﬁnding the adequate
antipsychotic, prevent random trials with different antipsychotics and
provide efﬁcacious and safe therapeutic treatment for schizophrenia
patients.
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.ygeno.2013.02.002.
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